Phase I/Ib study of carfilzomib and panobinostat with or without dexamethasone in patients with relapsed/refractory multiple myeloma
Elisabet E. Manasanch,
Jatin J. Shah,
Hans C. Lee,
Donna M. Weber,
Sheeba K. Thomas,
Behrang Amini,
Jasper Olsem,
Brandon Crumpton,
Ashley Morphey,
Zuzana Berkova,
Lei Feng,
Robert Z. Orlowski
Affiliations
Elisabet E. Manasanch
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
Jatin J. Shah
Karyopharm Therapeutics, Newton, MA
Hans C. Lee
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
Donna M. Weber
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
Sheeba K. Thomas
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
Behrang Amini
Department of Diagnostic Radiology, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX
Jasper Olsem
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
Brandon Crumpton
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
Ashley Morphey
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
Zuzana Berkova
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
Lei Feng
Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX
Robert Z. Orlowski
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX;Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
